Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor

We have previously shown that platelet-produced thrombospondin-1 up-regulates the urokinase plasminogen activator and its receptor and promotes tumour cell invasion. Although tumour cells produce thrombospondin-1 in vivo, they produce only minimal amounts of thrombospondin-1 in vitro. To determine the effect of tumour cell-produced thrombospondin-1 in the regulation of the plasminogen/plasmin system and tumour cell invasion, we studied THBS-1 -transfected MDA-MB-435 breast cancer cells that overexpress thrombospondin-1. The role of urokinase plasminogen receptor in thrombospondin-1-mediated adhesion and invasion was studied by antisense inhibition, enzymatic cleavage and antibody neutralization. Tumour cell adhesion to collagen and laminin was evaluated. Tumour cell invasion was studied in a modified Boyden chamber collagen invasion assay. Tumour cell thrombospondin-1 induced a 2–7 fold increase in urokinase plasminogen activator receptor and cell-associated urokinase plasminogen activator expression and a 50–65% increase in cell-associated urokinase plasminogen activator and plasmin activities. Furthermore, tumour cell thrombospondin-1 promoted tumour cell invasion and decreased tumour cell adhesion through up-regulation of urokinase plasminogen activator receptor-controlled urokinase plasminogen activator and plasmin activities. We conclude that tumour cell-produced thrombospondin-1 may play a critical role in the regulation of tumour cell adhesion and tumour cell invasion. © 2000 Cancer Research Campaign

• Publication year

  2000

• Venue

  British Journal of Cancer

• Publication date

  2000-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1054/bjoc.2000.1268PMID 10917542PMCID 2374573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombospondin Causes Activation of Latent Transforming Growth Factor-Secreted by Endothelial Cells by a Novel Mechanism

  2002cited by this paper
• Localization of the Disulfide Bonds in the NH 2-terminal Domain of the Cellular Receptor for Human Urokinase-type Plasminogen Activator

  2001cited by this paper
• Plasma thrombospondin levels in patients with colorectal carcinoma

  1998cited by this paper
• The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.

  1998cited by this paper
• The Effect of Thrombospondin-1 and TGF-β1 on Pancreatic Cancer Cell Invasion

  1998cited by this paper
• Adhesive proteins and the hematogenous spread of cancer.

  1997cited by this paper
• Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy

  1997cited by this paper
• Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors.

  1997cited by this paper
• Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.

  1997cited by this paper
• Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.

  1997influential reference
• Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

  1997cited by this paper
• The role of thrombospondin-1 in tumor progression and angiogenesis.

  1996cited by this paper
• Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.

  1996cited by this paper
• Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor‐1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues

  1996influential reference
• Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.

  1996cited by this paper
• Cellular Receptors in the Regulation of Plasmin Generation

  1995cited by this paper
• Thrombospondin and transforming growth factor‐beta 1 increase expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor‐1 in human MDA‐MB‐231 breast cancer cells

  1995cited by this paper
• Immunohistochemical localization of the plasminogen activator inhibitor‐1 in breast cancer

  1995cited by this paper
• The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen.

  1995cited by this paper
• Plasma thrombospondin levels in patients with gynecologic malignancies

  1994cited by this paper
• The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.

  1994cited by this paper
• Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor

  1994cited by this paper
• Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells

  1994cited by this paper
• Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system.

  1994cited by this paper
• Computer-assisted image analysis of tumor sections for a new thrombospondin receptor.

  1994cited by this paper
• Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.

  1994cited by this paper
• Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma.

  1994cited by this paper
• Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.

  1994cited by this paper
• The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.

  1994cited by this paper
• Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma.

  1994cited by this paper
• The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta.

  1994cited by this paper
• Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins.

  1993cited by this paper
• Thrombospondin causes activation of latent transforming growth factor- beta secreted by endothelial cells by a novel mechanism [published erratum appears in J Cell Biol 1993 Sep;122(5):following 1143]

  1993cited by this paper
• Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains.

  1993cited by this paper
• Biology and biochemistry of proteinases in tumor invasion.

  1993cited by this paper
• Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.

  1993cited by this paper
• Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast.

  1993cited by this paper
• Molecular mechanisms of protease‐mediated tumor invasiveness

  1993cited by this paper
• The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma.

  1993cited by this paper
• Molecular mechanisms of protease-mediated tumor invasiveness.

  1993cited by this paper
• Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.

  1993cited by this paper
• Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness

  1993cited by this paper
• Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.

  1992cited by this paper
• Increase of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in plasma after thrombolytic therapy of patients with myocardial infarction. A randomised, placebo-controlled study

  1992cited by this paper
• Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.

  1992cited by this paper
• Prognostic impact and clinical relevance of tumor associated proteases in breast cancer

  1992cited by this paper
• Plasminogen Activator Inhibitor Type 1: Biochemistry and Evidence for Modulation of Fibrinolysis In Vivo

  1992cited by this paper
• Thrombospondin Levels in Patients with Malignancy

  1992cited by this paper
• Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

  1992cited by this paper
• Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction.

  1991cited by this paper
• Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.

  1991cited by this paper
• In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion

  1991influential reference
• The plasminogen activator/plasmin system.

  1991cited by this paper
• Growth Factors in the Regulation of Plasminogen-Plasmin System in Tumor Cells

  1991cited by this paper
• Plasminogen Activation by Receptor-Bound Urokinase

  1991cited by this paper
• Spectrophotometric quantitation of anchorage-dependent cell numbers using the bicinchoninic acid protein assay reagent.

  1990cited by this paper
• The urokinase receptor and regulation of cell surface plasminogen activation.

  1990cited by this paper
• Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA.

  1990cited by this paper
• The role of urokinase-type plasminogen activator in aggressive tumor cell behavior

  1990cited by this paper
• Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

  1990cited by this paper
• Growth factors in the regulation of pericellular proteolysis: a review.

  1989cited by this paper
• Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin

  1988cited by this paper
• Ultrastructural localization of plasma membrane-associated urokinase- type plasminogen activator at focal contacts

  1988cited by this paper
• A rapid in vitro assay for quantitating the invasive potential of tumor cells.

  1987cited by this paper
• Thrombospondin, a potentiator of tumor cell metastasis.

  1987cited by this paper
• Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells

  1987cited by this paper
• Thrombospondin promotes cell-substratum adhesion.

  1987cited by this paper
• The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type

  1986cited by this paper
• A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

  1985cited by this paper

• Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation

  2023cites this paper
• High Expression of THBS1 Leads to a Poor Prognosis in Papillary Thyroid Cancer and Suppresses the Anti-Tumor Immune Microenvironment

  2022cites this paper
• Molecular Mechanisms of Antiproliferative and Apoptosis Activity by 1,5-Bis(4-Hydroxy-3-Methoxyphenyl)1,4-Pentadiene-3-one (MS13) on Human Non-Small Cell Lung Cancer Cells

  2021cites this paper
• Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival

  2021cites this paper
• Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity

  2021cites this paper
• Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers.

  2020cites this paper
• Tumor Microenvironment: Extracellular Matrix Components – Part B

  2020cites this paper
• Thrombospondin in Tumor Microenvironment.

  2020cites this paper
• THBS1 facilitates colorectal liver metastasis through enhancing epithelial–mesenchymal transition

  2020cites this paper
• Bioprinting of 3D breast epithelial spheroids for human cancer models

  2019cites this paper
• Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells

  2019cites this paper
• Thrombospondins and remodeling of the tumor microenvironment

  2018cites this paper
• Intervenolin suppresses gastric cancer cell growth through the induction of TSP-1 secretion from fibroblast-like stromal cells.

  2018cites this paper
• Thrombospondin-1 is a multifaceted player in tumor progression.

  2017cites this paper
• A possible IDO1- TSP1 role in breast cancer dormancy

  2017cites this paper
• Thrombospondin-1 is a multifaceted player in tumor progression

  2017cites this paper
• Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion

  2014cites this paper
• Thrombospondin-1 Modulates Actin Filament Remodeling and Cell Motility in Mouse Mammary Tumor cells in Vitro

  2014cites this paper
• Mécanismes de progression des carcinomes de la prostate et recherche de nouveaux facteurs pronostiques

  2013cites this paper
• Role of the protein tyrosine phosphatase DEP-1 in Src activation and the mediation of biological cell functions of endothelial and breast cancer cells

  2012cites this paper
• Matricellular Proteins: A Sticky Affair with Cancers

  2012cites this paper
• Thrombospondin-1-derived 4N1K peptide expression is negatively associated with malignant aggressiveness and prognosis in urothelial carcinoma of the upper urinary tract

  2012cites this paper
• Application of a human bone engineering platform to an in vitro and in vivo breast cancer metastasis model

  2011cites this paper
• CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo

  2011cites this paper
• CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo

  2010cites this paper
• Expression of thrombospondin-1 in human pancreatic adenocarcinomas: Role in matrix metalloproteinase-9 production

  2009cites this paper
• The effect of thrombospondin-1 on breast cancer metastasis

  2009cites this paper
• The role of angiocidin in sarcomas

  2009cites this paper
• VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.

  2009cites this paper
• Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells.

  2008cites this paper
• Regulation of Angiogenesis and Tumor Growth by Thrombospondin-1

  2008cites this paper
• Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity.

  2008cites this paper
• Thrombospondins: from structure to therapeutics

  2008cites this paper
• The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer.

  2007cites this paper
• HYPOXIA AND ANGIOGENESIS IN PANCREATIC CANCER

  2006cites this paper
• Cell Motility in Cancer Invasion and Metastasis

  2006cites this paper
• In Vitro Matrices for Studying Tumor Cell Invasion

  2006cites this paper
• The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.

  2005cites this paper
• Thrombospondin 1, an autocrine regulator in T cell adhesion and migration

  2005cites this paper
• Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1

  2005cites this paper
• Invasive potency related to RCAS1 expression in uterine cervical cancer.

  2005cites this paper
• Lack of telopeptides in fibrillar collagen I promotes the invasion of a metastatic breast tumor cell line.

  2005cites this paper
• Mechanisms of Thrombospondin-1-Mediated Metastasis and Angiogenesis

  2004cites this paper
• Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.

  2004cites this paper
• Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma

  2004cites this paper
• Mechanisms of thrombospondin-1-mediated metastasis and angiogenesis.

  2004cites this paper
• Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth.

  2004cites this paper
• Functional relationship and gene ontology classification of breast cancer biomarkers.

  2003cites this paper
• Thrombospondin-1 and Cutaneous Melanoma

  2003cites this paper
• Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients

  2003cites this paper
• Functional Relationship and Gene Ontology Classification of Breast Cancer Biomarkers

  2003cites this paper
• Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.

  2002cites this paper
• The Role of Thymidine Phosphorylase and Thrombospondin-1 in Angiogenesis and Progression of Intrahepatic Cholangiocarcinoma

  2002cites this paper
• Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.

  2002cites this paper
• Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma.

  2002cites this paper
• Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis.

  2001cites this paper
• The Role of Thrombospondin-1 in Tumor Progression

  2001cites this paper
• New developments in the urokinase-type plasminogen activator system

  2001cites this paper